Michael Mason - Jun 1, 2021 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
EVP, CFO, Treasurer
Signature
/s/ Nancy Smith as Attorney-in-Fact for Michael Mason
Stock symbol
KPTI
Transactions as of
Jun 1, 2021
Transactions value $
$0
Form type
4
Date filed
6/1/2021, 05:53 PM
Next filing
Feb 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Award $0 +5.5K +10.63% $0.00 57.3K Jun 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KPTI Stock Option (right to buy) Award $0 +15K $0.00 15K Jun 1, 2021 Common Stock 15K $9.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning June 1, 2022.
F2 This option was granted on June 1, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on June 1, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.